Jianming Jimmy Hao, Ph.D. writes:

A patent battle between University of California and MIT has casted clouds over the ownership of the CRISPR gene-editing technology potentially worth billions of dollars.  Bio-pharma companies, investors, and researchers should use caution when navigating the complex intellectual property landscape.

The CRISPR gene-editing technology has created intense excitement in the